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Abstract 
Body dysmorphic disorder (BDD) is a common and distressing or impairing preoccupation with a 
perceived defect in physical appearance. Individuals with BDD engage in time-consuming rituals 
to check, hide, or “fix” their appearance or alleviate distress. BDD is associated with substantial 
psychosocial impairment and high rates of depression, hospitalization, and suicidality.  
Cognitive-behavioral therapy (CBT) is the treatment of choice for BDD, but not everyone 
benefits. We examined predictors of CBT-related improvement, an important topic that has 
received very limited investigation. Treatment was delivered in weekly individual sessions over 
18-22 weeks. Results indicated that greater motivation/readiness to change (University of 
Rhode Island Change Assessment Questionnaire), greater treatment expectancy (Treatment 
Credibility/Expectancy Questionnaire), and better baseline BDD-related insight (Brown 
Assessment of Beliefs Scale)  significantly predicted better CBT response at post-treatment. 
Baseline BDD symptom severity and depression did not predict outcome, suggesting that even 
patients with more severe BDD and depressive symptoms can benefit from CBT for BDD. Efforts 
should be aimed at enhancing readiness to change and confidence in the treatment at 
treatment onset as well as addressing the poor insight that often characterizes BDD.  
Keywords: body dysmorphic disorder; BDD; cognitive behavioral therapy; predictors; treatment  
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Predictors of Response to Cognitive-Behavioral Therapy for Body Dysmorphic Disorder 
Body dysmorphic disorder (BDD) is a common, severe disorder characterized by 
distressing or impairing preoccupation with perceived imperfections in one’s physical 
appearance and time-consuming rituals (e.g., excessive mirror checking, cosmetic surgery 
seeking) aimed at checking, hiding, or fixing “flaws.” BDD is associated with substantial 
impairment in psychosocial functioning, and high rates of depression, hospitalization, and 
suicidality (Phillips & Menard, 2006; Philllips, Menard, Fay, & Pagano, 2005; Phillips, Quinn, & 
Stout, 2008).   
 Six randomized controlled trials have demonstrated the efficacy of cognitive-behavioral 
therapy (CBT) for BDD, with response rates ranging from 48% to 82% (Enander et al., 2016; 
Rabiei, Mulkens, Kalantari, Molavi, & Bahrami, 2012; Rosen, Reiter, & Orosan, 1995; Veale, 
Anson, Miles, Pieta, & Costa, 2014; Veale et al., 1996; Wilhelm et al., 2014). Thus, while CBT for 
BDD is effective, not everyone improves or improves fully. Additionally, BDD often requires a 
longer treatment (e.g., 22 sessions) than do many other conditions, thus utilizing significant 
resources. Identifying predictors of CBT response could inform important targets to address 
prior to or at the onset of treatment to optimize outcome. Very little research has evaluated 
predictors of treatment response for BDD. Therefore, our research questions were informed by 
(a) the few studies that have examined this topic, (b) predictors of CBT for obsessive compulsive 
disorder (OCD), and (c) clinical experience.  
 BDD has similarities to OCD (Phillips et al., 2007; Phillips et al., 2010) and is classified as 
an obsessive-compulsive and related disorder in the Diagnostic and Statistical Manual for 
Mental Disorders (DSM-5; American Psychiatric Association, 2013), thus findings on predictors 
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of CBT response in OCD may be informative. Several studies have examined predictors of 
outcome for OCD. More severe OCD was the most consistent predictor of poorer CBT outcomes 
for OCD (see Keijsers, Hoogduin, & Schaap, 1994; Knopp, Knowles, Bee, Lovell, & Bower, 2013; 
Kyrios, Hordern, & Fassnacht, 2015; Öst, Havnen, Hansen, & Kval, G, 2015; Steketee et al., 
2011), but has not reliably predicted outcome (Olatunji, Davis, Powers, & Smits, 2013; Steketee, 
Siev, Yovel, Lit, & Wilhelm, in press). Other clinical variables, including comorbid depression 
(Abramowitz, Franklin, Street, Kozak, & Foa, 2000; Keijsers et al., 1994; Thiel et al., 2014) and 
anxiety (Steketee et al., 2011), insight (Himle, Van Etten, Janeck, & Fischer, 2006; Raffin et al., 
2009) and greater functional impairment (Steketee et al., 2011; Steketee et al., in press) have 
also been shown to predict poorer outcome, but these findings have not been consistently 
replicated (Olatunji et al., 2013). Finally, patient and treatment factors have been implicated as 
predictors of treatment outcome. Several studies have found that higher motivation predicted 
better outcome to both CBT and pharmacotherapy for OCD (de Haan et al., 1997; Keijsers et al., 
1994; Pinto, Pinto, Neziroglu, & Yaryura-Tobias, 2007; Steketee et al., 2011). Patient expectancy 
about treatment has also been highlighted as a potential source of variance in treatment 
effects, although it did not predict outcome in five studies of CBT for OCD (Basoglu et al., 1988; 
Freeston et al., 1997; Lax, Basoglu, & Marks, 1992; Steketee et al., 2011; Vogel, Hansen, Stiles, 
& Götestam, 2006). Thus, overall, results of studies of predictors of outcome are largely 
equivocal.  
 Although OCD and BDD share many similarities, they also have important differences, 
such as poorer insight and more frequent comorbidity with depression and substance use 
disorders in BDD (Phillips et al., 2007). From a clinical perspective, many individuals with BDD 
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are ambivalent about receiving CBT due to such factors as low insight and depression. BDD-
related insight is usually poor or absent, with about 70% currently reporting poor insight or 
delusional BDD-related beliefs (e.g., complete conviction that “I look like a monster”; Eisen, 
Phillips, Coles, & Rasmussen, 2004; Phillips, 2004; Phillips, McElroy, Keck, Pope, & Hudson, 
1994). This can make it difficult for individuals with BDD to engage in a psychological treatment 
in which the focus is on changing one’s perception of appearance rather than on changing 
actual physical appearance. Major depressive disorder is the most common comorbid disorder 
in BDD (lifetime rates of 75–82%), and depressive symptoms (e.g., anhedonia, low energy, 
difficulty concentrating, hopelessness) can thwart one’s motivation or engagement in CBT 
(Gunstad & Phillips, 2003; Phillips, Menard, Pagano, Fay, & Stout, 2006). BDD is also associated 
with significant psychosocial impairment, with many patients avoiding activities, stopping work, 
dropping out of school, and even becoming housebound (Phillips et al., 2005).  
To our knowledge, only two prior studies have examined predictors of response to CBT 
in BDD. One small study showed that poor BDD-related insight predicted poorer outcome with 
behavior therapy for BDD (Neziroglu, Stevens, McKay, & Yaryura-Tobias, 2001). In a randomized 
controlled trial of CBT versus anxiety management for BDD, none of the baseline predictor 
variables examined (duration of BDD, depression, and BDD-related insight) significantly 
predicted outcome (Veale e al., 2014). In addition, a recent meta-analysis of seven randomized 
controlled trials of CBT for BDD (six studies with an adult sample, including Veale et al., 2014,  
and one with an adolescent sample; Harrison, Fernández de la Cruz, Enander, Radua, & Mataix-
Cols, 2016) found no reliable predictors of CBT outcome for BDD in a meta-regression that 
included pre-treatment BDD severity, comorbidities, insight, number of CBT sessions and 
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therapy hours, use of medication, previous cosmetic procedures, gender, age, and duration of 
BDD). Equivocal findings may be attributed to methodological differences across studies, 
including the treatment mode (i.e., individual vs. group, in-person vs. internet-based), content, 
duration, or intensity (e.g., weekly vs. daily intensive) or perhaps to primary (i.e. Yale-Brown 
Obsessive Compulsive Scale Modified for BDD [BDD-YBOCS] vs. Body Dysmorphic Disorder 
Examination- Self Report [BDDE-SR]) and assessment of potential predictive features (e.g., 
depressive symptoms, insight).  
 The aim of the current report is to identify predictors of CBT for BDD using data from 
two studies: 1) an uncontrolled pilot trial of CBT and 2) a subsequent randomized waiting-list 
controlled trial of CBT for BDD (Wilhelm et al. 2011; Wilhelm et al., 2014). Based on clinical 
experience and previous research on outcome predictors for BDD and OCD, we examined BDD 
symptom severity, BDD-related insight, depressive symptoms, functional impairment, and 
motivational factors as potential predictors of improvement at post-treatment. Given the 
limited and largely equivocal findings on predictors in BDD or OCD, this investigation is 
considered exploratory.  
Understanding how individuals differentially respond to treatment will increase 
understanding of whether CBT for BDD may be more or less efficacious for subgroups of BDD 
patients, ultimately permitting clinicians to provide more personalized treatment. CBT may not 
be the optimal treatment for all individuals with BDD (Harrison et al., 2016). CBT for BDD is 
relatively long (e.g., 22 sessions) and can be challenging. Understanding who would most likely 
benefit might provide a basis for future treatment development efforts for various subgroups 
of individuals with BDD who may require supplemental pre-treatment strategies to optimize 
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CBT preparedness and outcome. 
 Methods 
Participants 
Participants for this secondary data analysis came from an uncontrolled pilot trial (n=12; 
Wilhelm et al., 2011) and a subsequent waiting list-controlled trial (n=36; Wilhelm et al., 2014) 
of CBT for BDD. Because the pilot and waitlist-controlled trial samples were very similar in 
recruitment methods, inclusion/exclusion criteria, and demographic characteristics, they were 
combined to increase power. Participants were 48 adults (age 18 or older) with a primary DSM-
IV diagnosis of BDD or its delusional variant and a score on the BDD-YBOCS (Phillips et al., 1997) 
greater than or equal to 24 at enrollment. Exclusion criteria included active and clinically 
significant suicidality as determined by a clinician and/or score on the suicide item (#9) of the 
Beck Depression Inventory (Beck, Steer, & Brown, 1996) > 1,  a psychotic disorder (excluding 
delusional BDD), bipolar disorder, borderline personality disorder, substance abuse or 
dependence within the past three months, cognitive impairment that could interfere with one’s 
ability to participate fully in CBT (e.g., estimated IQ <80 on the Wechsler Abbreviated Scale of 
Intelligence [WASI, Wechsler, 1999]), self-reported dementia or brain damage, body 
image/weight concerns accounted for primarily by an eating disorder, concurrent 
psychotherapy, or a history of at least 10 sessions of CBT for BDD that resembled treatment 
provided in this study. Participants taking psychotropic medication were included if they 
reported a stable dose for at least two months prior to the initial evaluation and agreed to not 
change their medication during the study. For participants assigned to the waiting list, data 
from the CBT treatment that they received following the waiting list period were used in the 
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analyses. Of the 48 participants enrolled in either study, four were excluded from the current 
analyses because they dropped out of the study before treatment and baseline assessment 
(n=3) or before their first assessment after starting treatment (n=1), resulting in a final sample 
size of 44. 
Measures 
All participants attended an initial assessment with a doctoral-level independent 
evaluator (IE) to obtain informed consent and confirm eligibility. The initial assessment included 
a standardized semi-structured interview with an IE and completion of self-report measures. 
Scales were administered before, during (monthly), and after treatment (post-treatment and at 
three- and six-month follow up), unless otherwise noted below. To minimize dropout, 
participants received $25 for follow-up assessments.   
The Structured Clinical Interview for DSM-IV-Patient Version (SCID-I/P, First, Spitzer, 
Gibbon, & Williams, 1995) is a widely-used clinician-administered, semi-structured interview 
used to assess the presence of DSM-IV Axis I psychiatric disorders.   
The BDD-YBOCS is a 12-item semi-structured clinician-administered measure of BDD 
symptom severity that has demonstrated good internal consistency, high test-retest reliability, 
and good convergent validity (Phillips et al., 1997; Phillips, Hart, & Menard, 2014). The scale’s 
maximum score is 48, with higher scores indicating more severe BDD symptoms. The BDD-
YBOCS was the primary measure of treatment outcome. Internal consistency in the current 
sample was α=.79 for total scores at baseline, and the inter-rater reliability for participants in 
the wait-list controlled trial was r=.93 for 15% of taped interviews rated independently 
(Wilhelm et al., 2014). Responder status was classified using the empirically defined cut-point 
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of a BDD-YBOCS reduction ≥ 30% (Phillips et al., 1997; Phillips et al., 2014) at post-treatment 
(week 24).   
The Brown Assessment of Beliefs Scale (BABS; Eisen et al., 1998) is a valid, reliable 7-
item semi-structured clinician-administered measure that assesses insight regarding BDD-
related beliefs (e.g., “I look deformed”). The first 6 items of the BABS are summed to obtain a 
total score ranging from 0 to 24, with higher scores reflecting poorer insight. The BABS has 
been shown to have high internal consistency, interrater reliability, and test-retest reliability 
(Eisen et al., 1998; Phillips, Hart, Menard, & Eisen, 2013). The internal consistency for baseline 
total scores in the current sample was α=.77, and inter-rater reliability for participants in the 
wait-list controlled trial was r=.90 for 15% of taped interviews rated independently. The BABS 
can also be used to derive a categorical classification of delusionality (yes/no), with delusional 
beliefs versus non-delusional beliefs indicated by a total score >18 plus a score of 4 on item 1 
(conviction).  
The Beck Depression Inventory (BDI-II; Beck et al., 1996) is a widely used 21-item self-
report scale that assesses the severity of depressive symptoms during the past two weeks. Total 
scale scores range from 0 to 63, with higher scores indicating greater symptom severity. The 
BDI-II has high internal consistency, test–retest reliability, and construct validity (Beck et al., 
1988; Beck et al., 1996). Internal consistency for baseline scores in the current sample was 
α=.94. 
The Sheehan Disability Scale (SDS; Sheehan, 1983) is a self-report measure of functional 
impairment/disability. Items 1-3 (disability in work, social life/leisure, and family life/home 
responsibilities) are scored from 0 (not at all) to 10 (extreme). The three items can be summed 
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to yield a total SDS score, ranging from 0 (unimpaired) to 30 (highly impaired). The SDS has 
been shown to have good internal consistency, and mental disorder diagnoses are consistently 
associated with higher SDS scores (Leon et al., 1992). In the current sample, the internal 
consistency at baseline among the three measures of disability was α=0.77 
 The University of Rhode Island Change Assessment Questionnaire (URICA) is a 32-item 
self-report questionnaire that measures motivation and readiness to change (McConnaughy, 
DiClemente, Prochaska, & Velicer, 1989; McConnaughy, Prochaska, & Velicer, 1983) on four 5-
point Likert scales (from 1= “strongly disagree” to 5= “strongly agree”). The URICA has 
demonstrated acceptable to good internal consistency and construct validity (e.g., Carey, 
Purnine, Maisto, & Carey, 1999; Field, Adinoff, Harris, Ball, & Carroll, 2009; Field, Duncan, 
Washington, & Adinoff, 2007; McConnaughy et al., 1983). In the current sample, the internal 
consistency of the four sub-scales (precontemplation, contemplation, action, and maintenance) 
at baseline ranged from α=0.70 (pre-contemplation) to α=0.87 (maintenance).  The four sub-
scales can be combined to yield a single readiness-to-change (RTC) score by subtracting the 
mean precontemplation score from the sum of the mean scores for the other three subscales 
(score range: -2 - 14; McConnaughy et al., 1983, 1989). Higher URICA-RTC scores indicate a 
greater readiness to change. 
 The Treatment Credibility/Expectancy Questionnaire is a widely-used  measure of a 
patient’s judgements of the credibility of the treatment and their expectations of change due to 
treatment (Borkovec & Nau, 1972; Devilly & Borkovec, 2000), reported as a mean credibility 
score (items 1-3; range 1= “not at all” to 10 = “very” as assessed, re-scaled to 1-9 to match 
previously published scores) and a single item expectancy score (“By the end of therapy, how 
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much improvement in your anxiety do you think will occur?”, range: 0-100%). The credibility 
sub-scale has been shown to have good internal consistency, both scores have good test-retest 
reliability, and the expectancy score, as part of a 3-item extended instrument, has also 
demonstrated good predictive validity for treatment outcomes (Devilly & Borkovec, 2000).  
Higher scores indicate higher credibility or expectation for improvement. The Treatment 
Credibility/Expectancy Questionnaire was administered at baseline (week 0).  
Treatment 
CBT for BDD (Wilhelm, Phillips, & Steketee, 2013) is a modular CBT designed to address 
the core symptoms of BDD (e.g., preoccupation with perceived appearance flaws, BDD-based 
rituals) as well as symptoms experienced by some but not all individuals with BDD (e.g., skin 
picking, surgery seeking). Participants received 18-22, 60-minute individual sessions of CBT for 
BDD that included: psychoeducation, case formulation, setting valued goals, motivational 
enhancement as needed, cognitive restructuring, exposure and ritual prevention, mindfulness 
and attentional retraining, and advanced strategies to modify self-defeating beliefs about the 
importance of appearance and to enhance self acceptance, self-esteem, and self-compassion. 
Clinicians used optional treatment modules with participants who had symptoms requiring 
specific strategies (e.g., cosmetic treatment seeking, depressive symptoms). All participants 
received relapse prevention (final two sessions) to learn how to prevent and react effectively to 
setbacks. Sessions were weekly, except for the last two sessions (relapse prevention), which 
were spaced two weeks apart. See Wilhelm et al. (2011, 2013, 2014) for a more detailed 
description of the treatment.  
Statistical Methods 
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We used univariate logistic regression models to identify significant baseline predictors 
of BDD-YBOCS treatment response at post-treatment (week 24). For participants who dropped 
out during treatment (n=3 (7%), one each after week 4, 8, and 16 assessments), we used their 
last post-baseline BDD-YBOCS assessment to evaluate their post-treatment response status; 
two more participants dropped out during treatment (after session 7 and 8, respectively) but 
provided week 24 assessment data. To assess the sensitivity of model outcomes to our missing 
data assumption, we also ran two alternative models: one assuming all people with missing 
data at week 24 were non-responders, and one assuming they were responders. Baseline 
predictors examined included: BDD-YBOCS total score; BABS total score and delusionality 
(yes/no); current major depressive episode (yes/no); BDI-II total score; SDS total score, as well 
as SDS Work, Social, and Family subscale scores; URICA readiness-to-change index; treatment 
credibility and expectancy scores; baseline psychiatric medication use; and baseline selective 
serotonin reuptake inhibitors (SSRI) use. We then combined the significant univariate predictors 
identified into multiple logistic regression models with no more than 2 predictors to stay within 
the recommended lower limit of 5-9 events per variable that is still likely to produce adequate 
model performance (Vittinghoff and McCulloch, 2007). We identified the best predictive model 
using the concordance index c (Steyerberg et al., 2010)), which can indicate whether model fit 
is poor (c<0.5), good (c>0.7), or strong (c>0.8). Scale scores were calculated if fewer than 20% of 
questions were unanswered, in which case missing values were set to the mean of all questions 
in that (sub-)scale. Cronbach’s alphas were reported as unstandardized coefficients. 
Significance was evaluated at a two-tailed p<0.05, and means are presented as raw means with 
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standard deviations unless otherwise noted. All analyses were performed using SAS (Version 
9.4 of the SAS System for Windows).   
Results 
Descriptive Characteristics at Study Baseline 
Table 1 summarizes the demographics and clinical characteristics of the study 
participants at baseline. The sample was 61% women, predominantly Caucasian, and had a 
mean age of 34.8 (SD=10.1). Study participants reported moderate-severe BDD symptoms, had 
experienced BDD for many years, and exhibited significant functional impairment, particularly 
in their social lives; almost a quarter (22%) of the participants currently had BDD beliefs that 
were classified as delusional (absent insight) (Table 1). Thirty-two participants (73%) had at 
least one current comorbid axis I disorder, and 34% of participants (n=15) had two or more Axis 
I disorders. The most common (>10%) current Axis I comorbidities were major depressive 
disorder (n=17, 39%), social anxiety disorder (n=9, 20%), dysthymia (n=7, 16%), generalized 
anxiety disorder (n=6, 14%), and specific phobia (n=6, 14%). Further sample characteristics are 
detailed in the primary outcome papers of each study (Wilhelm et al., 2011; Wilhelm et al., 
2014).    
Treatment response by Post-Treatment 
Out of 44 participants who started CBT-BDD and provided at least one post-baseline 
assessment, 73% (32/44) were treatment responders. Among the 14 baseline predictors we 
tested, three were significantly associated with treatment response at post-treatment: BABS 
total score, URICA-RTC score, and treatment expectancy (Table 2). For every unit of increase in 
BABS total score (i.e., poorer BDD-related insight), the odds of being a treatment responder at 
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post-treatment were 15% lower (OR=0.846, 95% CI: [0.718, 0.996]; Table 2). Interestingly, 
neither BABS delusionality as a categorical variable (yes/no) nor BDD symptom severity at 
baseline nor depression severity at baseline were significant predictors of post-treatment 
response, even though each of these predictors was significantly correlated with BABS total 
scores (BABS delusionality: r = 0.77; BDD-YBOCS: r = 0.45; BDI-II totals scores: r = 0.46).  
For every unit increase in the URICA-RTC index, the odds of being a post-treatment 
responder were 145% greater (OR=2.451, 95% CI: [1.278, 4.699]; Table 2). URICA-RTC scores 
were significantly negatively correlated with BABS total scores (r = -0.57) and BABS delusionality 
(r = -0.32), such that higher levels of motivation were associated with better insight. They were 
not significantly correlated with any other potential predictor (-0.25 < r < 0.25).   
Higher scores for treatment expectancy (confidence in the treatment) also increased the 
odds of treatment response, such that for every 10-point increase on the treatment expectancy 
scale, the odds of treatment response increased by 40% (10-units OR=1.411, 95%CI: [1.034, 
1.924]; 1-unit OR=1.035, 95%CI: [1.003, 1.068]; Table 2). Treatment expectancy was positively 
correlated with the URICA-RTC (r= 0.45) and treatment credibility (r = 0.75) but not with any 
other predictor examined. Indicators of symptom severity, comorbidity, social functioning, or 
stable concurrent psychiatric medication use did not predict treatment response in this sample.   
Changing the missing data assumptions resulted in BABS total scores no longer being a 
significant predictor of treatment response (change from OR=0.846, 95%CI: [0.718-0.996] to 
OR=0.870, 95%CI: [0.746-1.015] when imputing all missing outcomes as non-responders, and to 
OR=0.894, 95%CI: [0.761-1.052] when imputing all missing outcomes as responders). Missing 
data assumptions also affected the significance of treatment credibility as a predictor of 
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treatment response, which became a significant predictor in the model assuming all missing 
outcomes were treatment non-responses (change from OR=1.664, 95%CI: [0.953-2.905] to 
OR=1.790, 95%CI: [1.017-3.152]), but not if missing outcomes were assumed to be responders 
(OR=1.821, 95%CI: [0.987-3.361]).  All other predictors remained either significant or non-
significant as before. 
Combining the three significant univariate predictors into three multiple logistic 
regressions with all combinations of 2 predictors indicated that the best predictive model of 
treatment response (c=0.81) used URICA-RTC (OR=2.180, 95%CI: [1.083, 4.390]) and treatment 
expectancy (1-unit OR=1.013, 95%CI: [0.978, 1.048]) as predictors. The models with URICA-RTC 
and BABS totals scores (c=0.79) and BABS total scores and treatment expectancy (c=0.77) had 
worse predictive accuracy, and only URICA-RTC remained a significant predictor of treatment 
response when combined with any other predictor.   
 
Discussion 
CBT is the best-supported psychosocial treatment for BDD. However, not all patients 
benefit. We found that greater baseline motivation/readiness to change and greater treatment 
expectancy were significant predictors of better post-treatment CBT for BDD response. Poorer 
BDD-related insight at baseline significantly predicted a lower chance of treatment response; 
however, insight was no longer significant in post-hoc sensitivity analyses using alternative 
assumptions about missing data. Our main model finding that poor BDD-related insight predicts 
poorer outcome is consistent with one prior study in BDD (Neziroglu et al., 2001); two studies 
of OCD (Raffin et al., 2009; Himle et al.,2006) also found this. However, another study of CBT for 
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BDD did not find that poorer insight predicted CBT response, although statistical power was 
limited (n=46, 13 responders; Veale et al., 2014). Thus, the relationship between BDD-related 
insight and treatment outcome is not entirely clear.  
Readiness/motivation to change was a particularly powerful predictor of treatment 
outcome; a single unit of increase in the URICA-RTC more than doubled the odds of treatment 
response. This variable and treatment expectancy have not yet been examined in relation to 
CBT outcome in BDD. However, our results align with several studies of OCD, which showed 
that motivation to change predicted better treatment outcome (de Haan et al., 1997; Keijsers 
et al., 1994; Pinto et al., 2007; Steketee et al., 2011). Whereas studies of OCD suggest that 
treatment expectancy does not predict outcome (Basoglu et al., 1988; Freeston et al., 1997; Lax 
et al., 1992; Steketee et al., 2011; Vogel et al., 2006), in the current study greater baseline 
expectations of treatment effectiveness predicted better outcome. It is interesting that greater 
readiness/motivation to change scores were significantly negatively correlated with insight (r = 
-0.57; BABS total score) and delusionality (r = -0.320); this finding is consistent with clinical 
observations that patients who cannot acknowledge that their appearance beliefs are 
inaccurate or that they might have BDD are often less motivated or ready to participate in a 
psychological treatment that requires them to invest substantial effort in the treatment; many 
prefer cosmetic treatments instead, which are usually ineffective (Crerand, Sarwer, & Ryan, 
2017). 
Clinical implications of these findings are that at treatment onset efforts to enhance 
readiness/motivation to change and confidence in the treatment may be particularly helpful.  
For patients with low readiness to change, particularly those with poor insight, employing 
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strategies such as motivational interviewing or pharmacotherapy with a serotonin reuptake 
inhibitor prior to initiating CBT may help to optimize outcome. In addition, the role of pre-
treatment expectancy as predictor of improvement may point to helpful educational strategies 
to deploy prior to initiating treatment, for example, by providing patients with positive 
treatment outcome data from prior studies and a compelling rationale for the use of specific 
CBT treatment elements..  
Initial BDD symptom severity, depression, and impairment in psychosocial functioning 
were not significant predictors of post-treatment outcome, consistent with the results from a 
recent meta-analysis (Harrison et al., 2016) and the Veale et al. (2014) trial, in which baseline 
depression did not predict response.  These results suggest that even individuals with severe 
BDD, severe depression, and high levels of functional impairment can be treated successfully 
with CBT for BDD. This is encouraging, given the frequency of comorbid major depressive 
disorder and often high levels of depression, as well as substantial functional impairment, in 
individuals with BDD. Our results support previous findings that depression and psychosocial 
impairment improve in response to a targeted CBT for BDD, without requiring additional 
treatment (Enander et al., 2016; Veale et al., 2014; Wilhelm et al., 2011; Wilhelm et al., 2014). 
However, it should be noted that the treatment manual used in the studies in this report 
includes an optional treatment module for individuals with more severe depressive symptoms, 
which can be used at any point during treatment if indicated. It is recommended that clinicians 
use similar strategies (i.e., activity scheduling incorporating valued goals and cognitive 
restructuring of depressive thoughts) when treating individuals with BDD who have moderate 
or severe depressive symptoms. As individuals with more severe depressive symptoms may be 
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more likely to drop out of treatment (Wilhelm et al., 2014), the use of such strategies may 
potentially enhance treatment retention.  
Taken together, CBT for BDD is often efficacious even for those who are severely ill, 
depressed, and functionally impaired (none of which significantly predicted treatment 
outcome). However, because these patients may be at greater risk for dropping out of 
treatment early, specific strategies, such as behavioral activation, in addition to motivational 
enhancement, may be needed early and often to ensure these individuals receive the full 
treatment.   
Limitations of the current study include the exploratory nature of the analyses and the 
relatively small sample, which limited statistical power. Given the small sample size and low 
number of non-responders (12/44), we did not control for multiple comparisons in analyses, 
which may have resulted in an inflated Type I error. We intended this secondary analysis to be 
hypothesis-generating rather than hypothesis-testing, so the predictors identified herein should 
be interpreted with caution. Replication in a larger sample is necessary. Thus far, most studies 
examining predictors of treatment response in BDD and related disorders have relied on 
relatively small samples and often examine different variables as putative predictors. Larger 
studies using a standardized pool of variables and assessment tools would help to elucidate any 
potential reliable predictors of treatment outcome. Eligibility in the parent studies (Wilhelm et 
al., 2011; Wilhelm et al., 2014) was broader than in previous studies of CBT for BDD (e.g., 
including both male and female participants and those with poor insight or passive suicidal 
ideation). Nonetheless, individuals with active suicidality were excluded. Given the markedly 
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high rates of suicidal ideation and attempts in BDD (Phillips & Menard, 2006), it would be useful 
to explore in future studies how suicidality influences and is impacted by CBT for BDD. In 
addition, self-esteem is often notably poor in BDD (Hartmann, Thomas, Greenberg, Matheny, & 
Wilhelm, 2014; Phillips, Pinto, & Jain, 2004) and has predicted treatment response in some 
studies in eating disorders (Cooper et al., 2016; Wild et al., 2016), which overlap somewhat 
with BDD. The role of self-esteem on BDD treatment outcome has not been examined and 
could be considered in future studies. Finally, clinical experience and some empirical data 
suggest that the presence of personality disorders can thwart CBT response. For example, 
schizotypal and obsessive compulsive personality disorders have been shown to predict poor 
outcome of CBT for OCD (Fricke et al., 2006; Moritz et al., 2004; Minichiello, Baer, & Jenike, 
1987; Pinto et al., 2011) or symptom recurrence at one-year follow-up (Steketee et al., 2011), 
one study found that a diagnosis of OCPD predicted better CBT for OCD outcome (Gordon, 
Salkovskis, & Bream, 2016). The occurrence of OCPD and schizotypal PD was too rare in the 
current sample (n=4 and n=0, respectively) to model the impact of their presence on treatment 
response. Future studies should examine the potential impact of Axis II comorbidity on BDD 
treatment outcome.  
BDD is an often severe and debilitating disorder. Effective treatments are available; 
however, response rates vary, and common symptoms of BDD (e.g., poor insight) may preclude 
individuals from engaging fully in the treatment. Thus, there is room to improve outcomes and 
deliver more individually tailored treatment approaches. For example, treatment developers 
could amplify and further enhance motivational enhancement strategies and include strategies 
to enhance readiness and expectations for change in the treatment -- strategies that therapists 
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can also employ in clinical settings prior to initiation of treatment. Technology-based solutions 
may provide a brief, inexpensive, scalable opportunity to enhance individuals’ preparedness for 
CBT, for example by increasing cognitive flexibility (Jalal et al., 2018) and motivation (e.g. 
Albright,Adam, Serri, Bleeker, & Goldman, 2016). Largely equivocal findings on predictors of 
outcome for BDD to date may also highlight a need to look beyond typical demographic and 
clinical variables. Interestingly, a recent neuroimaging study found that baseline functional 
connectivity patterns within the default mode and visual networks predicted CBT response in 
OCD, explaining up to 67% of the variance, and were stronger predictors than clinical scores 
(Reggente et al., 2018). Such work is needed in BDD to determine whether non-clinical factors, 
such as a resting state scan, might predict treatment outcome and thus facilitate optimal 
treatment planning. Replication of the current findings in larger samples and further 
exploration of other putative predictors would facilitate clinical decision-making and help 
optimize outcomes for individuals suffering from BDD.  
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Table 1 
Baseline characteristics 
Variables n(%) M(SD) 
Demographics 
    
 
Age, years 
  
34.8 (10.1) 
 
Men, % 17 (39) 
  
 
Race   
  
      White, % 38 (88)   
      Black, % 3 (7)   
      Other, % 2 (5)   
 
Education, years 
  
16.8 (2.6) 
BDD characteristics 
    
 
BDD age of onset, years, M(SD) 
  
18.1 (8.9) 
 BDD duration, years, M(SD)   16.8 (9.4) 
 
BDD-YBOCS total score, M(SD) 
  
30.6 (5.7) 
 
BABS total score, M(SD) 
  
14.0 (4.6) 
 BABS delusionality, % 10 (23)   
Psychiatric comorbidities 
    
 
Axis I comorbidity, % 32 (73) 
  
 
Current major depressive disorder, % 17 (39) 
  
 
BDI-II total, M(SD) 
  
20.9 (13.8) 
Psychiatric medication use 
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Current use of psychiatric medications, % 14 (31.8) 
  
 
Antidepressant use, % 11 (25.0) 
  
 
Benzodiazepine use, % 4 (9.1) 
  
 SSRI use, % 8 (18.2)   
Functioning 
    
 
SDS total score, M(SD) 
  
17.5 (6.9) 
 
SDS family sub-scale mean, M(SD) 
  
5.0 (3.1) 
 
SDS social sub-scale mean, M(SD) 
  
7.2 (2.2) 
 
SDS work sub-scale mean, M(SD) 
  
5.2 (2.9) 
Treatment expectations and experience 
    
 
URICA-RTC, M(SD) 
  
10.0 (1.7) 
 Treatment credibility mean score, M(SD)   6.1 (1.3) 
 
Treatment expectancy score, M(SD) 
  
62.4 (23.8) 
Responder status 
    
 
BDD-YBOCS Responder, post-treatment, M(SD) 32 (73) 
  
  BDD-YBOCS Responder, 6-month follow-up, M(SD) 30 (86)     
 
Note. BDD = body dysmorphic disorder; BDD-YBOCS = Yale-Brown Obsessive Compulsive Scale 
Modified for BDD; BABS = Brown Assessment of Beliefs Scale; BDI-II = Beck Depression 
Inventory-II; SDS = Sheehan Disability Scale global functioning score; URICA-RTC = University of 
Rhode Island Change Assessment Questionnaire readiness-to-change score.    
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Table 2 
Univariate logistic regression predictors of treatment response at post-treatment (week 24), as measured by a ≥30% reduction in 
BDD-YBOCS scores 
  Post-treatment (n=44) 
Baseline predictors Wald Χ2 p OR 95% LCL 95% UCL 
BDD-YBOCS total score 0.38 0.54 0.961 0.847 1.090 
BABS total score 4.04 0.04 0.846 0.718 0.996 
BABS delusionality 0.05 0.83 0.840 0.178 3.967 
BDI-II total score 1.56 0.21 0.969 0.922 1.018 
Current major depressive episode 2.59 0.11 0.325 0.083 1.277 
SDS total score 0.64 0.42 0.960 0.868 1.061 
SDS family sub-scale mean 0.51 0.47 0.923 0.740 1.150 
SDS social sub-scale mean 0.70 0.40 0.869 0.625 1.207 
SDS work sub-scale mean 0.45 0.50 0.922 0.726 1.171 
URICA-RTC 7.29 0.01 2.451 1.278 4.699 
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Treatment credibility mean score 3.20 0.07 1.664 0.953 2.905 
Treatment expectancy score 4.72 0.03 1.035 1.003 1.068 
Current psychiatric medication use 1.65 0.20 3.000 0.560 16.070 
Current SSRI use 0.99 0.32 3.080 0.337 28.130 
 
Note. BDD = body dysmorphic disorder; BDD-YBOCS = Yale-Brown Obsessive Compulsive Scale Modified for BDD; BABS = Brown 
Assessment of Beliefs Scale; BDI-II = Beck Depression Inventory-II; SDS = Sheehan Disability Scale global functioning score; URICA-
RTC = University of Rhode Island Change Assessment Questionnaire readiness-to-change score; SSRI = selective serotonin reuptake 
inhibitors. 
 
